Roche's Divarasib Shows Statistically Significant Progression-Free And Overall Survival Gains Versus Sotorasib Or Adagrasib In NSCLC Study
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed Statistical sign